From screen to target: Insights and approaches for the development of anti-virulence compounds

Frontiers in Cellular and Infection Microbiology

Volumn 4, Issue SEP, 2014, Pages

  Beckham, Katherine S H ^a   Roe, Andrew J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Anti Virulence; Escherichia coli; Infection; Inhibitor; Secretion

Indexed keywords

1 METHYLMOCIMYCIN; ANTIINFECTIVE AGENT; ANTIVIRULENCE COMPOUND; CYCLOSERINE; HYDRAZIDE DERIVATIVE; INP 0010; INP 0031; INP 0341; INP 0400; INP 0402; INP 0406; LUCIFERASE; ME 0052; ME 0055; SALICYLIDENE ACYLHYDRAZIDE; UNCLASSIFIED DRUG;

ACTIN FILAMENT; AFFINITY CHROMATOGRAPHY; ANTIBACTERIAL ACTIVITY; APOPTOSIS; ARTICLE; BACTERIAL LOAD; CHLAMYDIA; CITROBACTER RODENTIUM; DRUG DESIGN; DRUG SCREENING; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ENTEROPATHOGENIC ESCHERICHIA COLI; ERWINIA; GENE DELETION; GENE EXPRESSION; HOST PATHOGEN INTERACTION; ISOTHERMAL TITRATION CALORIMETRY; METABOLOMICS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PATHOGENICITY; PATHOGENICITY ISLAND; PROTEIN EXPRESSION; PROTEIN METABOLISM; REGULATORY MECHANISM; SALMONELLA ENTERICA; SHIGELLA FLEXNERI; STREPTOMYCES; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE; TYPE III SECRETION SYSTEM; ULTRACENTRIFUGATION; VIRULENCE; X RAY CRYSTALLOGRAPHY; YERSINIA; YERSINIA PSEUDOTUBERCULOSIS; BACTERIAL INFECTIONS; BACTERIAL SECRETION SYSTEM; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; INFECTION; METABOLISM; MICROBIOLOGY;

ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; BACTERIAL SECRETION SYSTEMS; DRUG DISCOVERY; HOST-PATHOGEN INTERACTIONS; HUMANS; INFECTION; VIRULENCE;

EID: 84907017504     PISSN: None     EISSN: 22352988     Source Type: Journal    
DOI: 10.3389/fcimb.2014.00139     Document Type: Article

References (30)

1. Allen, R. C., Popat, R., Diggle, S. P. and Brown, S. P. (2014). Targeting virulence: can we make evolution proof drugs? Nat. Rev. Microbiol. 12, 300-308.
2. Baron, C. (2006). VirB8: a conserved type IV secretion system assembly factor and drug target. Biochem. Cell Biol. 84, 890-899.
3. Beckham, K. S. H., Connolly, J. P. R., Ritchie, J. M., Wang, D., Gawthorne, J. a, Tahoun, A., Gally, D. L., Burgess, K., Burchmore, R. J., Smith, B. O., et al. (2014). The metabolic enzyme AdhE controls the virulence of Escherichia coli O157:H7. Mol. Microbiol. 93, 199-211. doi:10.1111/mmi.12651.
4. Deng, W., Puente, J. L., Gruenheid, S., Li, Y., Vallance, B. a, Va´zquez, A., Barba, J., Ibarra, J. A., O'Donnell, P., Metalnikov, P., et al. (2004). Dissecting virulence: systematic and functional analyses of a pathogenicity island. Proc. Natl. Acad. Sci. U. S. A. 101, 3597-602. doi:10.1073/pnas.0400326101.
5. Gabrielsen, M., Beckham, K. S. H., Feher, V. a, Zetterstro¨m, C. E., Wang, D., Mu¨ller, S., Elofsson, M., Amaro, R. E., Byron, O., and Roe, A. J. (2012). Structural characterisation of Tpx from Yersinia pseudotuberculosis reveals insights into the binding of salicylidene acylhydrazide compounds. PLoS One 7, e32217. doi:10.1371/journal.pone.0032217.
6. Halouska, S., Chacon, O., Fenton, R. J., Zinniel, D. K., Barletta, R. G., and Powers, R. (2007). Use of NMR metabolomics to analyze the targets of D-cycloserine in mycobacteria: Role of D-alanine racemase. J. Proteome Res. 6, 4608-4614. doi:10.1021/pr0704332.
7. Hudson, D. L., Layton, A. N., Field, T. R., Bowen, A. J., Wolf-Watz, H., Elofsson, M., Stevens, M. P., and Galyov, E. E. (2007). Inhibition of type III secretion in Salmonella enterica serovar Typhimurium by small- molecule inhibitors. Antimicrob. Agents Chemother. 51, 2631-5. doi:10.1128/AAC.01492-06.
8. Hueck, C. J. (1998). Type III Protein Secretion Systems in Bacterial Pathogens of Animals and Plants. Microbiol. Mol. Biol. Rev. 62, 379-433.
9. Iwatsuki, M., Uchida, R., Yoshijima, H., Ui, H., Shiomi, K., Kim, Y., Hirose, T., Sunazuka, T., Abe, A., Tomoda, H., et al. (2008). Guadinomines, Type III secretion system inhibitors, produced by Streptomyces sp. K01-0509. I: taxonomy, fermentation, isolation and biological properties. J. Antibiot. (Tokyo). 61, 222-9. doi:10.1038/ja.2008.32.
10. Kauppi, A. M., Nordfelth, R., Uvell, H., Wolf-watz, H., and Elofsson, M. (2003). Targeting Bacterial Virulence?: Inhibitors of Type III Secretion in Yersinia. 10, 241-249. doi:10.1016/S.
11. Kimura, K., Iwatsuki, M., Nagai, T., Matsumoto, A., Takahashi, Y., Shiomi, K., Omura, S., and Abe, A. (2011). A small-molecule inhibitor of the bacterial type III secretion system protects against in vivo infection with Citrobacter rodentium. J. Antibiot. (Tokyo). 64, 197-203. doi:10.1038/ja.2010.155.
12. Kondo, T., and Hirohashi, S. (2006). Application of highly sensitive fluorescent dyes (CyDye DIGE Fluor saturation dyes) to laser microdissection and two-dimensional difference gel electrophoresis (2D-DIGE) for cancer proteomics. Nat. Protoc. 1, 2940-2956. doi:10.1038/nprot.2006.421.
13. Layton, A. N., Hudson, D. L., Thompson, A., Hinton, J. C. D., Stevens, J. M., Galyov, E. E., and Stevens, M. P. (2010). Salicylidene acylhydrazide- mediated inhibition of type III secretion system-1 in Salmonella enterica serovar Typhimurium is associated with iron restriction and can be reversed by free iron. FEMS Microbiol. Lett. 302, 114-22. doi:10.1111/j.1574-6968.2009.01847.x.
14. Lindler, L. 2004. Virulence plasmids of Yersinia: characteristics and comparison, p.423-437. In B. E. Funnel and G. J. Phillips (ed.), Plasmid biology. ASM Press, Washington, DC.
15. Linington, R. G., Robertson, M., Gauthier, A., Finlay, B. B., MacMillan, J. B., Molinski, T. F., van Soest, R., and Andersen, R. J. (2002). Caminosides B-D, antimicrobial glycolipids isolated from the marine sponge Caminus sphaeroconia. Org. Lett. 4, 4089-4092. doi:10.1021/np050192h.
16. Martinez-Argudo, I., Veenendaal, A. K. J., Liu, X., Roehrich, a D., Ronessen, M. C., Franzoni, G., van Rietschoten, K. N., Morimoto, Y. V, Saijo- Hamano, Y., Avison, M. B., et al. (2013). Isolation of Salmonella mutants resistant to the inhibitory effect of Salicylidene acylhydrazides on flagella- mediated motility. PLoS One 8, e52179. doi:10.1371/journal.pone.0052179.
17. McDaniel, T. K., Jarvis, K. G., Donnenberg, M. S., and Kaper, J. B. (1995). A genetic locus of enterocyte effacement conserved among diverse enterobacterial pathogens. Proc. Natl. Acad. Sci. U. S. A. 92, 1664-1668.
18. Muschiol, S., Bailey, L., Gylfe, A., Sundin, C., Hultenby, K., Bergstro¨m, S., Elofsson, M., Wolf-Watz, H., Normark, S., and Henriques-Normark, B. (2006). A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis. Proc. Natl. Acad. Sci. U. S. A. 103, 14566-71. doi:10.1073/pnas.0606412103.
19. Negrea, A., Bjur, E., Ygberg, S. E., Elofsson, M., Wolf-Watz, H., and Rhen, M. (2007). Salicylidene acylhydrazides that affect type III protein secretion in Salmonella enterica, serovar typhimurium. Antimicrob. Agents Chemother. 51, 2867-76. doi:10.1128/AAC.00223-07.
20. Nordfelth, R., Kauppi, A. M., Norberg, H. A., and Elofsson, M. (2005). Small- Molecule Inhibitors Specifically Targeting Type III Secretion. 73, 3104- 3114. doi:10.1128/IAI.73.5.3104.
21. Slepenkin, A., Enquist, P.-A., Ha¨gglund, U., de la Maza, L. M., Elofsson, M., and Peterson, E. M. (2007). Reversal of the antichlamydial activity of putative type III secretion inhibitors by iron. Infect. Immun. 75, 3478-89. doi:10.1128/IAI.00023-07.
22. Slepenkin, A., Chu, H., Elofsson, M., Keyser, K., and Peterson, E. M. (2011). Protection of Mice From a Chlamydia trachomatis Vaginal Infection Using a Salicylidene acylhydrazide, a Potential Microbicide. J. Infect. Dis. 204, 1313-20.
23. Smith, M. a, Coinc¸on, M., Paschos, A., Jolicoeur, B., Lavalle´e, P., Sygusch, J., and Baron, C. (2012). Identification of the binding site of Brucella VirB8 interaction inhibitors. Chem. Biol. 19, 1041-8. doi:10.1016/j.chembiol.2012.07.007.
24. Tree, J. J., Wang, D., McInally, C., Mahajan, A., Layton, A., Houghton, I., Elofsson, M., Stevens, M. P., Gally, D. L., and Roe, A. J. (2009). Characterization of the effects of salicylidene acylhydrazide compounds on type III secretion in Escherichia coli O157:H7. Infect. Immun. 77, 4209-20. doi:10.1128/IAI.00562-09.
25. ur-Rehman, T., Slepenkin, A., Chu, H., Blomgren, A., Dahlgren, M.K., Zetterstrom, C. E., Peterson, E.M., Elofsson, M., and Gylfe, A. (2012) Pre-clinical pharmacokinetics and anti-chlamydial activity of salicylidene acylhydrazide inhibitors of bacterial type III secretion. J. Antibiot. 65, 397- 404; doi:10.1038/ja.2012.43
26. Veenendaal, A. K. J., Sundin, C., and Blocker, A. J. (2009). Small-molecule type III secretion system inhibitors block assembly of the Shigella type III secreton. J. Bacteriol. 191, 563-70. doi:10.1128/JB.01004-08.
27. Wang, D., Zetterstro, C. E., Gabrielsen, M., Beckham, K. S. H., Tree, J. J., Macdonald, S. E., Byron, O., Mitchell, T. J., Gally, D. L., Herzyk, P., et al. (2011). Identification of Bacterial Target Proteins for the Salicylidene Acylhydrazide Class of Virulence-blocking Compounds 286, 29922- 29931. doi:10.1074/jbc.M111.233858.
28. Wolf, K., Betts, H. J., Chellas-Ge´ry, B., Hower, S., Linton, C. N., and Fields, K. a (2006). Treatment of Chlamydia trachomatis with a small molecule inhibitor of the Yersinia type III secretion system disrupts progression of the chlamydial developmental cycle. Mol. Microbiol. 61, 1543-55. doi:10.1111/j.1365-2958.2006.05347.x.
29. Zhang, X., McDaniel, a D., Wolf, L. E., Keusch, G. T., Waldor, M. K., and Acheson, D. W. (2000). Quinolone antibiotics induce Shiga toxin- encoding bacteriophages, toxin production, and death in mice. J. Infect. Dis. 181, 664-70. doi:10.1086/315239.
30. Zhang, Z., Zong, C., Song, G., Lv, G., Chun, Y., Wang, P., Ding, N., and Li, Y. (2010). Total synthesis of caminoside B, a novel antimicrobial glycolipid isolated from the marine sponge Caminus sphaeroconia. Carbohydr. Res. 345, 750-60. doi:10.1016/j.carres.2010.01.015.